humanized antibody
antibodies from non-human species with protein sequences modified to make them nearly identical with human antibodies
≈ 4 min read
Names in other languages
- shHumanizovano antitelo
- СрпскиHumanizovano antitelo
- glAnticorpo humanizado
- ItalianoAnticorpo umanizzato
- Englishhumanized antibody
- EnglishHumanized antibody
- Englishhumanized antibody
- עבריתנוגדנים מואנשים
Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.
Humanized antibodies are antibodies from non-human species whose protein sequences have been modified to increase their similarity to antibody variants produced naturally in humans. The process of "humanization" is usually applied to monoclonal antibodies developed for administration to humans (for example, antibodies developed as anti-cancer drugs).
Humanization can be necessary when the process of developing a specific antibody involves generation in a non-human immune system (such as that in mice). The protein sequences of antibodies produced in this way are partially distinct from homologous antibodies occurring naturally in humans, and are therefore potentially immunogenic when administered to human patients (see also Human anti-mouse antibody).
Until 2021, the International Nonproprietary Names for new humanized antibodies ended in -zumab, as in omalizumab, but a new nomenclature has since been adopted, and new names now end in different stems (see Nomenclature of monoclonal antibodies). Humanized antibodies are distinct from chimeric antibodies.
The latter also have their protein sequences made more similar to human antibodies, but carry a larger stretch of non-human protein. There are other ways to develop monoclonal antibodies. This list covers many of the monoclonals developed for use in humans.
Derivation from sources other than mice
Some technologies completely avoid the use of mice or other non-human mammals in the process of discovering antibodies for human therapy. Examples of such systems include various "display" methods (primarily phage display) as well as methods that exploit the elevated B-cell levels that occur during a human immune response.
Display methods
These employ the selective principles of specific antibody production but exploit micro-organisms (as in phage display) or even cell-free extracts (as in ribosome display). These systems rely on the creation of antibody gene "libraries" which can be wholly derived from human RNA isolated from peripheral blood.
The immediate products of these systems are antibody fragments, normally Fab or scFv. This means that, although antibody fragments created using display methods are of fully human sequence, they are not full antibodies. Therefore, processes in essence identical to humanization are used to incorporate and express the derived affinities within a full antibody.
Adalimumab (Humira) is an example of an antibody approved for human therapy that was created through phage display.
Antibodies from human patients or vaccine recipients
It is possible to exploit human immune reaction in the discovery of monoclonal antibodies. Simply put, the human immune response works in the same way as that in a mouse or other non-human mammal.
Therefore, persons experiencing a challenge to their immune system, such as an infectious disease, cancer, or a vaccination are a potential source of monoclonal antibodies directed at that challenge. This approach seems especially apt for the development of anti-viral therapies that exploit the principles of passive immunity.
Variants of this approach have been demonstrated in principle and some are finding their way into commercial development.
See also
List of therapeutic monoclonal antibodies
Text derived from https://en.wikipedia.org/w/index.php?oldid=1369639932 under CC BY-SA 4.0; modifications have been made.